Sanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, have signaled their intent to work with the legal administrator of the COVAX Facility.
The two companies have vowed to produce 200 million doses of a vaccine based on the protein subunit AS03 adjuvant.
Governments, businesses and health organizations have banded together to support the COVAX Facility, which aims to ensure global equitable access to vaccines to treat the novel coronavirus.
The initiative could potentially address the development of vaccine nationalism, the nationalistic tendency to prioritize vaccines that could cost the world $1.2 trillion, according to estimates from the Rand Europe.
The two companies announced their plan to supply up to 60 million doses to the U.K.
The vaccine candidate from the Franco-British partnership, however, trails rivals with Phase 3 COVID-19 vaccine trials including Moderna (NSDQ:MRNA), Janssen (NYSE:JNJ), Pfizer (NYSE:PFE) and AstraZeneca (LON:AZN).
Sanofi and GSK launched a Phase 1/2 trial on September 3 with 440 subjects enrolled. The companies anticipate first results from that trial in early December 2020. Sanofi and GSK hope to launch a Phase 3 trial before the end of 2020.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
